A Series C financing round of 18 MUSD was finalized in May 2016.
A Series B financing round of 8 MUSD was finalized in September 2014.
A Series A financing round of 14 MCHF was finalized in April 2012.
Main investors are:
BiomedInvest II, managed by BioMedPartners in Basel, Switzerland (www.biomedvc.com)
BB Biotech Ventures III, managed by BB Biotech in Kuesnacht, Switzerland (www.bbbiotechventures.com)
Initiative Capital Romandie, managed by Defi Gestion in Lausanne, Switzerland (www.defigestion.com)
BV5 FPCI, managed by Banexi Venture Partners in Paris, France (www.banexiventures.com)
Greatbatch Inc. (NYSE: GB) (www.greatbatch.com)
ALEVA NEUROTHERAPEUTICS SA | EPFL INNOVATION PARK - BUILDING D | 1015 LAUSANNE
| SWITZERLAND | INFO@ALEVA-NEURO.COM